| | english | español | français |
Go to record ID

  Home|Finding Information|Record details   Printer-friendly version

Second Regular National Report on the Implementation of the Cartagena Protocol on Biosafety
Record information and status
Record ID
102990
Status
Published
Date of creation
2012-01-11 21:15 UTC (andrew.bowers@cbd.int)
Date of publication
2012-01-11 21:15 UTC (andrew.bowers@cbd.int)

This document is also available in the following languages:
Origin of report
Country
  • Panama
Contact officer for report
Coordinates
Marisol Dimas
Punto Focal PCSB
Autoridad Nacional del Ambiente
Zona 0843-00793 Ancón, Albrook Edificio 804
Panama City, Balboa
Panama
Phone:+507 500 0855
Fax:+507 500 0839
Email:m.dimas@anam.gob.pa
Consulted stakeholders
9. Organizations/stakeholders who were consulted or participated in the preparation of this report
ES
Amarilys Cruz - Autoridad Panameña sobre Seguridad de Alimentos.

Dario Luque - Autoridad Nacional el Ambiente. Itza Broce - Ministerio de Relaciones Exteriores.

Judith Ivette Vargas- Ministerio de Desarrollo Agropecuario.

Liliana Guerra y Thelma Quintero - Autoridad de los Recursos Acuáticos de Panamá.

Marisol Dimas - Autoridad Nacional del Ambiente
Submission
10. Date of submission
2011-09-30
11. Time period covered by this report
Start date
2009
Time period covered by this report
End date
2011
Party to the Cartagena Protocol on Biosafety
12. Is your country a Party to the Cartagena Protocol on Biosafety (CPB)?
  • Yes
Article 2 – General provisions
15. Has your country introduced the necessary legal, administrative and other measures for the implementation of the Protocol?
  • A domestic regulatory framework is partially in place
16. Which specific instruments are in place for the implementation of your national biosafety framework?
  • One or more national biosafety laws
  • One or more national biosafety regulations
  • One or more sets of biosafety guidelines
  • Other laws, regulations or guidelines that indirectly apply to biosafety
17. Has your country established a mechanism for the budgetary allocations of funds for the operation of its national biosafety framework?
  • Yes
18. Does your country have permanent staff to administer functions directly related to the national biosafety framework?
  • Yes
19. If you answered Yes to question 18, how many permanent staff members are in place whose functions are directly related to the national biosafety framework?
  • More than 10
20. Has your country’s biosafety framework / laws / regulations / guidelines been submitted to the Biosafety Clearing-House (BCH)?
  • Partially
21. Here you may provide further details on the implementation of Article 2 in your country:
ES
La Repúlica de Panamá, a través de las Autoridades Competentes continuan dando seguimiento al proceso de fortalecimiento del marco legal e institucional para la aplicación del Protocolo de Cartagena sobre Seguridad en la Biotecnología.
Los instrumentos jurídicos establecidos para la aplicación del marco nacional de seguridad en la biotecnología son: la Ley 72 de 26 de diciembre de 2001, la Ley 48 de 8 de agosto de 2002. Se ha establecido el Comité Sectorial de Bioseguridad Agropecuario y se elabora su reglamentación. Las Autoridades Competentes que se mencionan en la Ley 48 de 2002, han iniciado la identificación de los reglamentos y directrices sobre seguridad de la biotecnología para los organismos vivos modificados. Actualmente, se revisan las solicitudes caso por caso.
Las Autoridades Competentes han asignado presupuesto de contrapartida en especie y en efectivo para la implementación del Proyecto de Consolidación de las Capacidades Nacionales para la plena implementación del Protocolo de Cartagena sobre Bioseguridad en Panamá.
A nivel institucional, participan cerca de 23 funcionarios que forman parte de la Comisión Nacional de bioseguridad, los Puntos Focales Nacionales y los Miembros del Comité Sectorial de Bioseguridad Agropecuario.
A través de la Autoridad Nacional del Amiente se han remitido las Leyes nacionales y contactos institucionales al Centro de Intercambio de Información sobre Seguridad en la Biotecnología. Los mismos se encuentran en la página Web del BCH. 
Article 5 – Pharmaceuticals
22. Does your country regulate the transboundary movement, handling and use of living modified organisms (LMOs) which are pharmaceuticals?
  • Yes, to some extent
23. If you answered Yes to question 22, has this information been submitted to the BCH?
  • No
24. Here you may provide further details on the implementation of Article 5 in your country:
ES
El Ministerio de Salud, a través del Departamento de Protección de Alimentos (DEPA)y el Ministerio de Desarrollo Agropecuario, a través de la Dirección Nacional de Salud Animal, son las autoridades competentes para regular los aspectos de manipulación y utilización de los productos farmacéuticos en el país.
Article 6 – Transit and Contained use
25. Does your country regulate the transit of LMOs?
  • Yes
26. Does your country regulate the contained use of LMOs?
  • Yes
27. If you answered Yes to questions 25 or 26, has this information been submitted to the BCH?
  • No
28. Here you may provide further details on the implementation of Article 6 in your country:
ES
El tránsito de los OVM a lo interno del país se atiende caso por caso. La Autoridad de los Recursos Acuaticos de Panamá (ARAP) bajo las directrices de la Comsión Nacional de Bioseguridad, aplica las normas internas para el tránsito de OVM a lo interno de país. Sin embargo, se requiere la formalización de los procedimientos de tránsito a nivel nacional por
el Comité Sectorial Agropecuario de Bioseguridad.
El uso confinado de OVM se atiende caso por caso en el pais. Existe un Protocolo de bioseguridad para el uso confinado de salmones transgénicos y para el uso contenido de "ensayo experimental" de híbridos de maíz genéticamente modificados.
El Proyecto "Transferencia y evaluación de la nueva alternativa de control de Aedes aegypti mediante el uso de mosquitos transgénicos en Panamá", presentó solicitud de importación ante el Ministerio de Desarrollo Agropecuario, a través del Instituto Conmemorativo Gorgas de Estudios en Salud, para investigación de uso contenido, remitida en febrero 2011, a la
Comisión Nacional de Bioseguridad. A través de la Presidencia de la Comsión Nacional de Bioseguridad se ha envidado nota de respuesta de recibo de la solicitud y se envío del formulario solicitando la información para hacer evaluación de la solicitud.
El estudio consiste en el uso de mosquitos transgénicos para el control de poblaciones de Aedes aegypti, capacitación en el extranjero de personal profesional en la cría y mantenimiento de colonias de mosquitos transgénicos, asesoría internacional para la transferencia e implementación de metodologías, protocolos y tecnología OXITEC RIDL al
Instituto Conmemorativo Gorgas de Estudios de la Salud (ICGES), que es una institución de salud pública establecida en Panamá desde 1921, dedicada principalmente a la investigación de la salud y prevención de enfermedades.
Articles 7 to 10 – Advance Informed Agreement (AIA) and intentional introduction of LMOs into the environment
29. Has your country adopted law(s) / regulations / administrative measures for the operation of the AIA procedure of the Protocol?
  • Yes
30. Has your country adopted a domestic regulatory framework consistent with the Protocol regarding the transboundary movement of LMOs for intentional introduction into the environment?
  • No
31. Has your country established a mechanism for taking decisions regarding first intentional transboundary movements of LMOs for intentional introduction into the environment?
  • No
33. Has your country established a mechanism for monitoring potential effects of LMOs that are released into the environment?
  • Yes
34. Does your country have the capacity to detect and identify LMOs?
  • Yes, to some extent
35. Has your country established legal requirements for exporters under its jurisdiction to notify in writing the competent national authority of the Party of import prior to the intentional transboundary movement of an LMO that falls within the scope of the AIA procedure?
  • Yes
36. Has your country established legal requirements for the accuracy of information contained in the notification?
  • Yes
37. Has your country ever received an application / notification regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
  • No
38. Has your country ever taken a decision on an application / notification regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
  • No
41. In the current reporting period, how many applications/notifications has your country received regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
  • None
42. In the current reporting period, how many decisions has your country taken regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
  • None
50. Here you may provide further details on the implementation of Articles 7-10 in your country, including measures in case of lack of scientific certainty on potential adverse effects of LMOs for intentional introduction to the environment:
ES
Las Autoridades Competentes tienen en cuenta el marco legal que ofrece la Ley 72 de 2001, sobre el Protocolo de Cartagena sobre la seguridad de la Biotecnología, como marco legal para aplicar el Procedimiento de Acuerdo fundamentado previo. A la fecha se ha solicitado la implementación de sendos protocolos para ensayos (dispersión de polen en otra área de estudio con híbridos NO genéticamente modificados e un inventario de la entomofauna nativa en lugar del ensayo de evaluación de las
caracteristicas agronómicas y dos características de eficacia biológica) en el caso de maíz geneticamente modificado.

Sobre los requisitos legales en cuanto a la exactitud de la información que figura en la notificación, se cuenta con un cuestionario que debe ser completado por el interesado y que debe ser evaluado por el Comité Sectorial de Bioseguridad Agropecuaria de la Autoridad Competente y la Comisión Nacional de Bioseguridad. Además, se adelanta la elaboración de un Manual de Gestión de Procesos que facilitará la toma de decisiones.
Article 11 – Procedure for living modified organisms intended for direct use as food or feed, or for processing (LMOs-FFP)
51. Has your country adopted specific law(s) or regulation(s) for decision-making regarding domestic use, including placing on the market, of LMOs-FFP?
  • No
52. Has your country established legal requirements for the accuracy of information to be provided by the applicant?
  • Yes
53. Has your country established a mechanism to ensure that decisions regarding LMOs-FFP that may be subject to transboundary movement will be communicated to the Parties through the BCH?
  • No
54. Has your country established a mechanism for taking decisions on the import of LMOs-FFP?
  • No
55. Has your country declared through the BCH that in the absence of a regulatory framework its decisions prior to the first import of an LMO-FFP will be taken according to Article 11.6 of the Cartagena Protocol on Biosafety?
  • No
56. Has your country indicated its needs for financial and technical assistance and capacity building in respect of LMOs-FFP?
  • Yes
57. Has your country ever taken a decision on LMOs-FFP (either on import or domestic use)?
  • No
63. Here you may provide further details on the implementation of Article 11 in your country, including measures in case of lack of scientific certainty on potential adverse effects of LMOs-FFP:
ES
A la fecha, la República de Panamá no ha adoptado una reglamentación específica para la adopción de decisiones relativas al uso racional incluida la colocación en el mercado de organismos vivos modificados.
Con relación a los requisitos legales respecto a la precisión de la información proporcionada por el solicitante, la Comisión Nacional de Bioseguridad ha dado las directrices para que la Autoridad Competente remita los requisitos de información para la introducción de arroz transgénico para consumo humano a consorcios interesados. Sin embargo, no se ha recibido respuesta para sea evaluado.
La República de Panamá cuenta con la Comisión Nacional de Bioseguridad como
mecanismo para asegurar que las Autoridades Competentes tomen las decisiones relativas a los OVM - AHAP, que pudieran ser objeto de un movimiento transfronterizo, sean comunicadas a través de la herramienta de BCH, pero no se ha formalizado el mecanismo para informar a través de CIISB.
La República de Panamá ha identificado las necesidades de asistencia financiera y técnica y la creación de capacidades respecto a los OVM-AHAP. A través del Punto Focal Nacional, se recomienda realizar una actualización de la identificación de necesidades de creación de
capacidades.
Article 12 – Review of decision
64. Has your country established a mechanism for the review and change of a decision regarding an intentional transboundary movement of LMOs?
  • No
65. Has your country ever received a request for a review of a decision?
  • No
66. Has your country ever reviewed / changed a decision regarding an intentional transboundary movement of LMOs?
  • No
67. In the current reporting period, how many decisions were reviewed and/or changed regarding an intentional transboundary movement of an LMO?
  • None
71. Here you may provide further details on the implementation of Article 12 in your country:
ES
La República de Panamá, a través de las Autoridades Competentes no ha realizado revisiones o cambios de decisiones relativas a un movimiento transfronterizo internacional de OVM y tampoco cuenta con un mecanismo específico para hacerlo.
Article 13 – Simplified procedure
72. Has your country established a system for the application of the simplified procedure regarding an intentional transboundary movement of LMOs?
  • No
73. Has your country ever applied the simplified procedure?
  • No
75. In the current reporting period, how many LMOs has your country applied the simplified procedure to?
  • None
76. Here you may provide further details on the implementation of Article 13 in your country:
ES
La República de Panamá no cuenta con un sistema para la aplicación del
Procedimiento simplificado para los movimientos transfronterizos intencionales de OVM. No obstante, se considera en las disposiciones de la Ley 72 de 2001, artículo 13.
Article 14 – Bilateral, regional and multilateral agreements and arrangements
77. Has your country entered into any bilateral, regional or multilateral agreements or arrangements?
  • No
Article 15 – Risk assessment
81. Has your country established a mechanism for conducting risk assessments prior to taking decisions regarding LMOs?
  • Yes
82. If you answered Yes to question 81, does this mechanism include procedures for identifying experts to conduct the risk assessments?
  • Yes
83. Has your country established guidelines for how to conduct risk assessments prior to taking decisions regarding LMOs?
  • Yes
84. Has your country acquired the necessary domestic capacity to conduct risk assessment?
  • No
85. Has your country established a mechanism for training national experts to conduct risk assessments?
  • No
86. Has your country ever conducted a risk assessment of an LMO for intentional introduction into the environment?
  • No
87. Has your country ever conducted a risk assessment of an LMO intended for direct use as food or feed, or for processing?
  • No
88. If your country has taken decision(s) on LMOs for intentional introduction into the environment or on domestic use of LMOs-FFP, were risk assessments conducted for all decisions taken?
  • Not applicable
89. Has your country submitted summary reports of the risk assessments to the BCH?
  • No
90. In the current reporting period, if your country has taken decisions regarding LMOs, how many risk assessments were conducted in the context of these decisions?
  • None
91. Has your country ever required the exporter to conduct the risk assessment(s)?
  • No
92. Has your country ever required the notifier to bear the cost of the risk assessment(s) of LMOs?
  • No
93. Here you may provide further details on the implementation of Article 15 in your country:
ES
La Comisión Nacional de Bioseguridad de la República de Panamá ha brindado las orientaciones para aplicar mecanismos de evalaución de riesgo antes de adoptar decisiones relativas a los OVM. Se han elaborado los modelos de formulario para análisis de riesgo y evaluaciones de riesgo, los mismos están en proceso de aprobación.
Para la realización de las evaluaciones de riesgo de OVM de uso agropecuario, el país cuenta con el Comité Sectorial de Bioseguridad Agropecuario conformado por expertos del Instituto de Investigación Agropecuaria de Panamá, la Autoridad de los Recursos Acuáticos de Panamá, la Dirección Nacional de Sanidad Vegetal, la Dirección Nacional de Salud Animal, el Comité Nacional de Semillas, la Autoridad Panameña de Seguridad de Alimentos y la Unidad Ambiental del Ministerio de Desarrollo Agropecuario. No obstante, la capacidad actual del país para realizar las evaluaciones de riesgo es limitada, no contamos con un mecanismo nacional de capacitación, los especialistas en el tema tienen que capacitarse en Universidades en otros país, por lo que se requiere fortalecer las capacidades institucionales para las evaluaciones de riesgo.
Article 16 – Risk management
94. Has your country established and maintained appropriate and operational mechanisms, measures and strategies to regulate, manage and control risks identified in risk assessments for:
94.1) LMOs for intentional introduction into the environment?
  • Yes
94.2) LMOs intended for direct use as food or feed, or for processing?
  • No
95. Has your country established and maintained appropriate measures to prevent unintentional transboundary movements of LMOs?
  • No
96. Has your country taken measures to ensure that any LMO, whether imported or locally developed, undergoes an appropriate period of observation that is commensurate with its life-cycle or generation time before it is put to its intended use?
  • Yes
97. Has your country cooperated with other Parties with a view to identifying LMOs or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity?
  • Yes
98. Has your country cooperated with other Parties with a view to taking measures regarding the treatment of LMOs or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity?
  • Yes
99. Here you may provide further details on the implementation of Article 16 in your country, including any details regarding risk management strategies, also in case of lack of scientific certainty on potential adverse effects of LMOs:
ES
Ejemplo: Salmon Aquadvantage

Contención Biológica (Biocontención): a. Validación del método de triploidía, b. Triploidía, Triploidización y Esterilación del Salmon Aquadvanyage, c. Poblaciones Femeninas, Monosexuales

Contención Geográfica y Geofísica de las instalaciones en el Centro de Producción de Huevos y/o alevines en Canada

Contención Geográfica y Geofísica en las instalaciones de investigación en Panamá.

Contención Mecánica: 21 barreras mecánicas en las instalaciones de la investigación.

Mosquito Aedes aegypti RIDL, investigación en condiciones confinadas en laboratorio bajo las normas de seguridad requeridas.
Article 17 – Unintentional transboundary movements and emergency measures
100. Has your country made available to the BCH the relevant details setting out its point of contact for the purposes of receiving notifications under Article 17?
  • Yes
101. Has your country established a mechanism for addressing emergency measures in case of unintentional transboundary movements of LMOs that are likely to have significant adverse effect on biological diversity?
  • Yes
102. Has your country implemented emergency measures in response to information about releases that led, or may have led, to unintentional transboundary movements of LMOs?
  • No
103. In the current reporting period, how many times has your country received information concerning occurrences that led, or may have led, to unintentional transboundary movement(s) of one or more LMOs to or from territories under its jurisdiction?
  • Never
107. Here you may provide further details on the implementation of Article 17 in your country:
ES
A través de la Comisión Nacional de Bioseguridad, los Puntos Focales nacionales y las Autoridades Competentes se ha recabado información sobre experiencias en otros países.
Por ejemplo: maíz transgénicos (evento DAS 01507, Maíz Herculex I), salmón transgénico y mosquitos transgénicos
Article 18 – Handling, transport, packaging and identification
108. Has your country taken measures to require that LMOs that are subject to transboundary movement are handled, packaged and transported under conditions of safety, taking into account relevant international rules and standards?
  • Yes, to some extent
109. Has your country taken measures to require that documentation accompanying LMOs-FFP clearly identifies that, in cases where the identity of the LMOs is not known through means such as identity preservation systems, they may contain living modified organisms and are not intended for intentional introduction into the environment, as well as a contact point for further information?
  • Yes, to some extent
110. Has your country taken measures to require that documentation accompanying LMOs-FFP clearly identifies that, in cases where the identity of the LMOs is known through means such as identity preservation systems, they contain living modified organisms and are not intended for intentional introduction into the environment, as well as a contact point for further information?
  • No
111. Has your country taken measures to require that documentation accompanying LMOs that are destined for contained use clearly identifies them as living modified organisms and specifies any requirements for the safe handling, storage, transport and use, the contact point for further information, including the name and address of the individual and institution to whom the LMO are consigned?
  • Yes
112. Has your country taken measures to require that documentation accompanying LMOs that are intended for intentional introduction into the environment of the Party of import, clearly identifies them as living modified organisms; specifies the identity and relevant traits and/or characteristics, any requirements for the safe handling, storage, transport and use, the contact point for further information and, as appropriate, the name and address of the importer and exporter; and contains a declaration that the movement is in conformity with the requirements of this Protocol applicable to the exporter?
  • No
113. Does your country have the capacity to enforce the requirements of identification and documentation of LMOs?
  • Yes, to some extent
114. Has your country established procedures for the sampling and detection of LMOs?
  • No
115. Here you may provide further details on the implementation of Article 18 in your country:
ES
La Comisión Nacional de Bioseguridad ha sugerido los requisitos para la
documentación que debe acompañar a los OVM-AHAP que se introduzcan al país, en los que se indica claramente que los OVM pueden llegar a contener organismos transgénicos y que no están destinados para su consumo humano o animal. Además, se han hecho recomendaciones para identificar en la documentación de introducción, que la misma no esta autorizada para la introducción y liberación al ambiente. Aún falta la adopción formal de este procedimiento.
Article 19 – Competent National Authorities and National Focal Points
116. Has your country designated one national focal point for the Cartagena Protocol to be responsible for liaison with the Secretariat?
  • Yes
117. Has your country designated one national focal point for the Biosafety Clearing-House to liaise with the Secretariat regarding issues of relevance to the development and implementation of the BCH?
  • Yes
118. Has your country designated one or more competent national authorities, which are responsible for performing the administrative functions required by the Cartagena Protocol on Biosafety and are authorized to act on your country’s behalf with respect to those functions?
  • Yes, more than one
119. In case your country designated more than one competent national authority, has your country conveyed to the Secretariat the respective responsibilities of those authorities?
  • Yes
120. Has your country made available the required information referred in questions 116-119 to the BCH?
  • Yes, all information
121. In case your country has designated more than one competent national authority, has your country established a mechanism for the coordination of their actions prior to taking decisions regarding LMOs?
  • Yes
122. Has your country established adequate institutional capacity to enable the competent national authority(ies) to perform the administrative functions required by the Cartagena Protocol on Biosafety?
  • Yes, to some extent
123. Here you may provide further details on the implementation of Article 19 in your country:
ES
La República de Panamá ha cumplido con la designación de los Puntos Focales
Nacionales para el Protocolo de Cartagena sobre Seguridad en la Biotecnología, para el centro e Intercambio de información sobre seguridad en la Biotecnología, de las Autoridades Competentes y sus puntos de contacto y las ha remitido a la Secretaria del CDB.
Article 20 – Information Sharing and the Biosafety Clearing-House (BCH)
124. Please provide an overview of the status of the information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH.
124.a) Existing national legislation, regulations and guidelines for implementing the Protocol, as well as information required by Parties for the advance informed agreement procedure (Article 20, paragraph 3 (a))
  • Information available but only partially available in the BCH
124.b) National laws, regulations and guidelines applicable to the import of LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 5)
  • Information available but only partially available in the BCH
124.c) Bilateral, multilateral and regional agreements and arrangements (Articles 14, paragraph 2 and 20, paragraph 3 (b))
  • Information not available
124.d) Contact details for competent national authorities (Article 19, paragraphs 2 and 3), national focal points (Article 19, paragraphs 1 and 3), and emergency contacts (Article 17, paragraph 3 (e))
  • Information available and in the BCH
124.e) Reports submitted by the Parties on the operation of the Protocol (Article 20, paragraph 3 (e))
  • Information available and in the BCH
124.f) Decisions by a Party on regulating the transit of specific living modified organisms (LMOs) (Article 6, paragraph 1)
  • Information available but not in the BCH
124.g) Occurrence of unintentional transboundary movements that are likely to have significant adverse effects on biological diversity (Article 17, paragraph 1)
  • Information not available
124.h) Illegal transboundary movements of LMOs (Article 25, paragraph 3)
  • Information not available
124.i) Final decisions regarding the importation or release of LMOs (i.e. approval or prohibition, any conditions, requests for further information, extensions granted, reasons for decision) (Articles 10, paragraph 3 and 20, paragraph 3(d))
  • Information available but not in the BCH
124.j) Information on the application of domestic regulations to specific imports of LMOs (Article 14, paragraph 4)
  • Information available but not in the BCH
124.k) Final decisions regarding the domestic use of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing (Article 11, paragraph 1)
  • Information not available
124.l) Final decisions regarding the import of LMOs intended for direct use as food or feed, or for processing that are taken under domestic regulatory frameworks (Article 11, paragraph 4) or in accordance with annex III (Article 11, paragraph 6) (requirement of Article 20, paragraph 3(d))
  • Information not available
124.m) Declarations regarding the framework to be used for LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 6)
  • Information not available
124.n) Review and change of decisions regarding intentional transboundary movements of LMOs (Article 12, paragraph 1)
  • Information not available
124.o) LMOs granted exemption status by each Party (Article 13, paragraph 1)
  • Information not available
124.p) Cases where intentional transboundary movement may take place at the same time as the movement is notified to the Party of import (Article 13, paragraph 1)
  • Information not available
124.q) Summaries of risk assessments or environmental reviews of LMOs generated by regulatory processes and relevant information regarding products thereof (Article 20, paragraph 3 (c))
  • Information not available
125. Has your country established a mechanism for strengthening the capacity of the BCH National Focal Point to perform its administrative functions?
  • Yes
126. Has your country established a mechanism for the coordination among the BCH National Focal Point, the Cartagena Protocol focal point, and the competent national authority(ies) for making information available to the BCH?
  • Yes
127. Does your country use the information available in the BCH in its decision making processes on LMOs?
  • Yes, always
128. Has your country experienced difficulties accessing or using the BCH?
  • No
129. If you answered Yes to question 128, has your country reported these problems to the BCH or the Secretariat?
  • Not applicable
130. Is the information submitted by your country to the BCH complete and up-to date?
  • No
131. Here you may provide further details on the implementation of Article 20 in your country:
ES
Se ha enviado al CIISB la información digital de las leyes nacionales que establecen los mecanismos de coordinación y funciones de los Puntos Focales y Autoridades Competentes. Sin embargo, está por iniciar la fase de implementación de creación de capacidades institucionales con el propósito de desarrollar la reglamentación y procedimientos complementarios sobre bioseguridad, a nivel sectorial y nacional
Article 21 – Confidential information
132. Has your country established procedures to protect confidential information received under the Protocol?
  • Yes
133. Does your country allow the notifier to identify information that is to be treated as confidential?
  • In some cases only
134. Here you may provide further details on the implementation of Article 21 in your country:
ES
La legislación nacional panameña, en materia de propiedad intelectual es aplicable al reconocimiento de la información confidencial. En particular, el Decreto Ejecutivo N°25 del 29 de abril de 2009 por el cual se reglamenta el artículo 71 de la Ley N°41 del 1 de julio de 1998, General del Ambiente. Gaceta Oficial Digital, No. 26272, que regula el acceso a los
recursos genéticos y que reconoce la propiedad intelectual.
Article 22 – Capacity-building
135. Has your country received external support or benefited from collaborative activities with other Parties in the development and/or strengthening of human resources and institutional capacities in biosafety?
  • Yes
136. If you answered Yes to question 135, how were these resources made available?
  • Bilateral channels
137. Has your country provided support to other Parties in the development and/or strengthening of human resources and institutional capacities in biosafety?
  • No
139. Is your country eligible to receive funding from the Global Environment Facility (GEF)?
  • Yes
140. Has your country ever initiated a process to access GEF funds for building capacity in biosafety?
  • Yes
141. If you answered Yes to question 140, how would you characterize the process?
Please add further details about your experience in accessing GEF funds under question 150.
  • Average
142. Has your country ever received funding from the GEF for building capacity in biosafety?
  • Pilot Biosafety Enabling Activity
  • Development of national biosafety frameworks
  • Implementation of national biosafety frameworks
  • Building Capacity for Effective Participation in the BCH (Phase I)
  • Building Capacity for Effective Participation in the BCH (Phase II)
143. During the current reporting period, has your country undertaken activities for the development and/or strengthening of human resources and institutional capacities in biosafety?
  • Yes
144. If you answered Yes to question 143, in which of the following areas were these activities undertaken?
  • Institutional capacity
  • Human resources capacity development and training
  • Risk assessment and other scientific and technical expertise
  • Risk management
  • Public awareness, participation and education in biosafety
  • Information exchange and data management including participation in the Biosafety Clearing-House
  • Scientific, technical and institutional collaboration at subregional, regional and international levels
  • Identification of LMOs, including their detection
  • Implementation of the documentation requirements under Article 18.2 of the Protocol
  • Taking into account risks to human health
145. During the current reporting period, has your country carried out a capacity-building needs assessment?
  • Yes
146. Does your country still have capacity-building needs?
  • Yes
147. If you answered Yes to question 146, indicate which of the following areas still need capacity-building.
  • Institutional capacity
  • Human resources capacity development and training
  • Risk assessment and other scientific and technical expertise
  • Risk management
  • Public awareness, participation and education in biosafety
  • Information exchange and data management including participation in the Biosafety Clearing-House
  • Scientific, technical and institutional collaboration at subregional, regional and international levels
  • Technology transfer
  • Identification of LMOs, including their detection
  • Socio-economic considerations
  • Implementation of the documentation requirements under Article 18.2 of the Protocol
  • Handling of confidential information
  • Measures to address unintentional and/or illegal transboundary movements of LMOs
  • Scientific biosafety research relating to LMOs
  • Taking into account risks to human health
148. Has your country developed a capacity-building strategy or action plan?
  • Yes
149. Has your country submitted the details of national biosafety experts to the Roster of Experts in the BCH?
  • No
150. Here you may provide further details on the implementation of Article 22 in your country, including further details about your experience in accessing GEF funds:
ES
La experiencia relativa a la gestión de financiamiento es regular. Se ha tenido mayor éxito en los proyectos multipaíses y en los proyectos de aplicación del mecanismo de facilitación del Protocolo. Hemos encontrado obstáculos en el proceso de gestión de financiamiento para proyectos de tamaño mediano, por lo complicado de los formatos y por cambios en los formatos para presentación de perfiles y documentos del proyecto
Article 23 – Public awareness and participation
151. Has your country established a strategy or put in place legislation for promoting and facilitating public awareness, education and participation concerning the safe transfer, handling and use of LMOs?
  • No
152. Has your country established a biosafety website?
  • Yes
153. Has your country established a mechanism to ensure public access to information on living modified organisms that may be imported?
  • No
154. Has your country established a mechanism to consult the public in the decision-making process regarding LMOs?
  • No
155. Has your country established a mechanism to make available to the public the results of decisions taken on LMOs?
  • Yes, to a limited extent
156. Has your country taken any initiative to inform its public about the means of public access to the Biosafety Clearing-House?
  • No
157. In the current reporting period, has your country promoted and facilitated public awareness, education and participation concerning the safe transfer, handling and use of LMOs?
  • No
159. In the current reporting period, how many times has your country consulted the public in the decision-making process regarding LMOs and made the results of such decisions available to the public?
  • None
160. Here you may provide further details on the implementation of Article 23 in your country:
ES
No contamos con una estrategia de sensibilización, educación y participación del público en lo que atañe a la seguridad de la transferencia, manipulación y utilización de los OVM. Se realizan actividades aisladas para sensibilizar a funcionarios públicos, estudiantes universitarios y comunicadores sociales en el tema del Protocolo de Cartagena sobre Seguridad en la Biotecnología y su aplicación.
Article 24 – Non-Parties
161. Has your country entered into any bilateral, regional, or multilateral agreement with non-Parties regarding transboundary movements of LMOs?
  • Yes
162. Has your country ever imported LMOs from a non-Party?
  • No
163. Has your country ever exported LMOs to a non-Party?
  • No
166. If your country is not a Party to the Cartagena Protocol, has it contributed information to the BCH on LMOs released in, or moved into, or out of, areas within its national jurisdiction?
  • Not applicable
167. Here you may provide further details on the implementation of Article 24 in your country:
ES
Panamá cuenta con acuerdos bilaterales que incluyen los aspectos comerciales y ambientales, así como el intercambio biotecnológico. Sin embargo, no se específica el tema de bioseguridad para la comercialización y consumo de los organismos genéticamente modificados.]
Article 25 – Illegal transboundary movements
168. Has your country adopted domestic measures aimed at preventing and/or penalizing transboundary movements of LMOs carried out in contravention of its domestic measures to implement this Protocol?
  • No
169. Has your country established a strategy for detecting illegal transboundary movements of LMOs?
  • No
170. In the current reporting period, how many times has your country received information concerning cases of illegal transboundary movements of an LMO to or from territories under its jurisdiction?
  • Never
175. Here you may provide further details on the implementation of Article 25 in your country:
ES
No se han detectado movimientos transfronterizo ilícitos.
Article 26 – Socio-economic considerations
176. If your country has taken a decision on import, has it ever taken into account socio-economic considerations arising from the impact of the LMO on the conservation and sustainable use of biological diversity?
  • No
177. Has your country cooperated with other Parties on research and information exchange on any socio-economic impacts of LMOs?
  • No
178. Here you may provide further details on the implementation of Article 26 in your country:
ES
No se han realizado evaluaciones enfocadas en los aspectos socioeconómicos.
Article 27 – Liability and Redress
179. Has your country signed the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress?
  • Yes
180. Has your country initiated steps towards ratification, acceptance or approval of the Nagoya-Kuala Lumpur Supplementary Protocol?
  • Yes
181. Here you may provide further details on any activities undertaken in your country towards the implementation of the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress:
ES
El país se encuentra en proceso de consulta con las entidades responsables para la ratificaicón del Protocolo Suplementario de Nagoya - Kuala Lumpur, sobre responsabilidad y compensación.
Article 33 – Monitoring and reporting
182. Has your country submitted the previous national reports (Interim and First National Reports)?
  • Yes, First report only
183. If your country did not submit previous reports, indicate the main challenges that hindered the submission
  • Other
Other information
184. Please use this field to provide any other information on issues related to national implementation of the Protocol, including any obstacles or impediments encountered.
ES
Los informes se remitieron en digital a la Secretaria del Convenio sobre la Diversidad Biológica y al Ministerio de Relaciones Exteriores de la República de Panamá, en el 2010.